癌・腫瘍プロファイリングの世界市場予測（～2024年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 19)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1.1 Markets Covered
1.3.1.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Limitations
2 Research Methodology (Page No. – 22)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 30)
4 Premium Insights (Page No. – 35)
4.1 Cancer/Tumor Profiling: Market Overview
4.2 Cancer/Tumor Profiling Market: Geographic Growth Opportunities
4.3 Regional Mix: Cancer/Tumor Profiling Market (2019–2024)
4.4 Cancer/Tumor Profiling Market: Developed vs Developing Markets (2019 vs 2024)
5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Cancer
5.2.1.2 Increasing Use of Biomarkers in Cancer Profiling
5.2.1.3 Increasing Cancer Research and Funding
5.2.1.4 Technological Advancements
5.2.2 Market Restraints
5.2.2.1 High Capital Investment
5.2.2.2 Technical Issues With Sample Collection and Storage
5.2.3 Market Opportunities
5.2.3.1 Increasing Demand for Personalized Medicine
5.2.3.2 Growing Need for Point-Of-Care Diagnostics
5.2.4 Market Challenges
5.2.4.1 Low Biomarker Discovery-To-Approval Ratio
5.2.4.2 Poor Regulatory and Reimbursement Scenario
6 Industry Insights (Page No. – 48)
6.1 Introduction
6.2 Industry Trends
6.2.1 Integration of Omics Data
6.2.2 Advances in Liquid Biopsy
6.2.3 Organoids for Personalized Medicine
7 Cancer/Tumor Profiling Market, By Technology (Page No. – 51)
7.1 Introduction
7.2 Immunoassays
7.2.1 Immunoassay Tests Identify and Assess the Progression of Disease, Thereby Providing Information Vital for Better Therapeutic Choices
7.3 Next-Generation Sequencing
7.3.1 Advances in NGS Multiplexing Capabilities Enable One Assay to Provide A Complete Tumor Molecular Profile
7.4 Polymerase Chain Reaction
7.4.1 Real-Time PCR Helps in the Quantification of Low-Copy Transcripts, Aiding Biomarker Identification
7.5 In Situ Hybridization
7.5.1 Fish is the Gold Standard for Evaluating Some Key Biomarkers and Plays A Critical Role in Guiding Targeted Therapies
7.6 Microarrays
7.6.1 Microarrays are Widely Adopted in Diagnostics as They AID in Predicting the Recurrence of Cancer After Treatment
7.7 Mass Spectrometry
7.7.1 Technological Advancements are Supporting the Adoption of This Technology for Sensitive, Reliable, and Rapid Diagnosis
7.8 Other Technologies
8 Cancer/Tumor Profiling Market, By Cancer Type (Page No. – 65)
8.1 Introduction
8.2 Breast Cancer
8.2.1 Breast Cancer is the Most Common Cancer Found Among Women
8.3 Lung Cancer
8.3.1 Molecular Characterization of Tumors Using NGS has is A Key Tool for the Clinical Management of Nsclc Patients
8.4 Colorectal Cancer
8.4.1 IHC, PCR, Microarrays, and Imaging Technologies are Major Technologies Used in Colorectal Diagnostics
8.5 Prostate Cancer
8.5.1 Prostate-Specific Antigen is A Widely Used Fda-Approved Biomarker for Prostate Cancer Screening
8.6 Melanoma
8.6.1 RT-QPCR is Generally Utilized to Conduct Molecular Profiling and Analyze Biomarkers in Melanomas
8.7 Other Cancers
9 Cancer/Tumor Profiling Market, By Biomarker Type (Page No. – 77)
9.1 Introduction
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers are Frequently Used in Clinical Practice for Diagnosis and Prognosis
9.3 Protein Biomarkers
9.3.1 Proteomic Methods Showcase Significant Promise for the Discovery of Novel Biomarkers
9.4 Other Biomarkers
10 Cancer/Tumor Profiling Market, By Application (Page No. – 84)
10.1 Introduction
10.2 Research Applications
10.2.1 Biomarker Discovery
10.2.1.1 Biomarkers are Being Exploited for the Development of Personalized Or Precision Medicine
10.2.2 Personalized Medicine
10.2.2.1 The Field of Personalized Medicine is Witnessing Rapid Growth in the Area of Oncology
10.3 Clinical Applications
10.3.1 Diagnostics
10.3.1.1 Tumor Profiling is Rapidly Gaining Momentum in the Area of Diagnostics
10.3.2 Prognostics
10.3.2.1 Advancements in Molecular Biology are Aiding the Uptake of Tumor Profiling in This Segment
10.3.3 Monitoring & Treatment
10.3.3.1 Multiplatform Profiling Analyses are Gaining Recognition for Monitoring and Treatment Among Cancer Patients
10.3.4 Screening
10.3.4.1 Screening Tests Help in Deciding If Diagnostic Tests are Required By the Patient
11 Cancer/Tumor Profiling Market, By Region (Page No. – 95)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 US Dominates the North American Cancer/Tumor Profiling Market
11.2.2 Canada
11.2.2.1 Growing Public-Private Partnerships to Promote Proteomics Research are Expected to Drive the Market in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Advancements Proteomics and Genomics Research are Expected to Drive Market Growth
11.3.2 UK
11.3.2.1 Growth in the Life Science Industry and the Increase in Academia-Industry Partnerships Will Be the Key Factors Driving the Market
11.3.3 France
11.3.3.1 Growth in This Market is Primarily Driven By Increasing Investments in Life Science R&D for Infrastructural Development
11.3.4 Italy
11.3.4.1 Increasing Investment in Cancer and Translational Research is Expected to Propel Market Growth During the Forecast Period
11.3.5 Spain
11.3.5.1 Rising Incidence of Cancer and Increasing Focus on Cancer Biomarkers By Various Medical Societies to Support Market Growth in Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.1.1 Large Number of Research Initiatives Towards the Development of Precision Medicine Supporting Market Growth in Japan
11.4.2 China
11.4.2.1 China has the Fastest-Growing Research Sector in the APAC Region
11.4.3 India
11.4.3.1 Increasing Pharma R&D and Government Funding in the Biotechnology Industry are the Major Factors Driving Market Growth in India
11.4.4 Rest of Asia Pacific
11.5 Latin America
11.5.1 Growing Proteomics Research in the Field of Cancer Along With the Rising Use of Advanced Techniques to Drive Market Growth
11.6 Middle East & Africa
11.6.1 Growing Genomics and Proteomics Research and Increasing Research Collaborations are Expected to Support Market Growth
12 Competitive Landscape (Page No. – 155)
12.1 Overview
12.2 Competitive Leadership Mapping
12.2.1 Visionary Leaders
12.2.2 Innovators
12.2.3 Dynamic Differentiators
12.2.4 Emerging Companies
12.3 Competitive Situation and Trends
12.3.1 Product Launches, Approvals, and Enhancements
12.3.2 Expansions
12.3.3 Acquisitions
12.3.4 Other Strategies
13 Company Profiles (Page No. – 162)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 Illumina, Inc.
13.2 Qiagen N.V.
13.3 Neogenomic Laboratories, Inc.
13.4 Sysmex Corporation
13.5 HTG Molecular Diagnostics, Inc.
13.6 Helomics Corporation
13.7 Genomic Health, Inc.
13.8 Caris Life Sciences
13.9 Nanostring Technologies, Inc.
13.10 Ribomed Biotechnologies, Inc.
13.11 Guardant Health, Inc.
13.12 Foundation Medicine
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies
14 Appendix (Page No. – 213)
14.1 Insights of Industry Experts
14.2 Market Sizing & Validation Approach
14.3 Discussion Guide
14.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details